GLP-1 receptor agonists have transformed obesity and diabetes treatment, but their therapeutic effects extend far beyond appetite suppression and glycemic control. This session takes a deeper look at the mechanisms behind GLP-1 efficacy—especially their impact on inflammation, neural signaling, and long-term physiology. A central focus will be the modulation of interleukin-6 (IL-6), a cytokine with both pro-inflammatory and homeostatic roles. While GLP-1 agents reduce IL-6 expression and resolve neuroinflammation, chronic suppression may carry trade-offs, including potential impacts on immune resilience, exercise adaptation, and lean body mass. This talk explores pharmacologic vs. physiologic GLP-1 activity, providing context for both the benefits and side effects—such as ophthalmic disease, pancreatitis, and sarcopenia. By integrating immunology, neurobiology, and clinical application, attendees will gain a systems-level understanding of GLP-1 therapy and a framework for more personalized, safer, and future-ready prescribing.

CME/CE Expiration Date: 4/12/29

*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.